Ascendis Pharma AS (MEX:ASNDN) Other Stockholders Equity: MXN9,998 Mil (As of Mar. 2026)


MEX:ASNDN Ascendis Pharma AS MEX:ASNDN
37 GF Score
Price MXN3,851.44
! 1 Warning Sign
View Full Analysis

What is Ascendis Pharma AS Other Stockholders Equity?

Ascendis Pharma AS MEX:ASNDN 37 Other Stockholders Equity is MXN9,998 Mil as of Mar. 2026. GuruFocus rates MEX:ASNDN with a GF Score™ of 37/100. The stock has 1 warning sign investors should review.

Ascendis Pharma AS's Other Stockholders Equity for the quarter that ended in Mar. 2026 was MXN9,998 Mil.

Ascendis Pharma AS's quarterly Other Stockholders Equity increased from Sep. 2025 (MXN-3,926 Mil) to Dec. 2025 (MXN-3,608 Mil) and increased from Dec. 2025 (MXN-3,608 Mil) to Mar. 2026 (MXN9,998 Mil).

Ascendis Pharma AS's annual Other Stockholders Equity increased from Dec. 2023 (MXN-2,840 Mil) to Dec. 2024 (MXN-2,486 Mil) but then declined from Dec. 2024 (MXN-2,486 Mil) to Dec. 2025 (MXN-3,608 Mil).

Ascendis Pharma AS Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Other Stockholders Equity Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20,305.13 5,280.30 -2,840.38 -2,486.41 -3,608.37

Ascendis Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 -3,926.33 -3,608.37 9,998.10
MEX:ASNDN
37GF Score
Ascendis Pharma AS MEX:ASNDN
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Pharma AS Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of MXN9,998 Mil mean?
Ascendis Pharma AS (MEX:ASNDN) has a Other Stockholders Equity of MXN9,998 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Ascendis Pharma AS and its competitors.
Is Ascendis Pharma AS's Other Stockholders Equity too high?
Ascendis Pharma AS's current Other Stockholders Equity is MXN9,998 Mil. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Other Stockholders Equity compare to SMMT and BBIO?
Ascendis Pharma AS's Other Stockholders Equity of MXN9,998 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current Other Stockholders Equity is MXN9,998 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (MEX:ASNDN) has a current Other Stockholders Equity of MXN9,998 Mil. The current Other Stockholders Equity is MXN9,998 Mil. Ascendis Pharma AS's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Ascendis Pharma AS (MEX:ASNDN), the current Other Stockholders Equity is MXN9,998 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Other Exchanges ASND:USA
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score

Get the complete analysis for MEX:ASNDN

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,851.44
Price